SCHEMBL1719485

SCHEMBL1719485

O=C(O)C1Cc2ccccc2CC(C(=O)O)C1=O

nearest known ligand 0.59

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.46
ALDH1A1 P00352 2/20 0.44
MAPT P10636 2/20 0.44
GAA P10253 1/20 0.44
TSHR P16473 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
FABP7 O15540 1/20 0.40
FABP5 Q01469 1/20 0.40
MMP3 P08254 1/20 0.39
MMP8 P22894 1/20 0.39
LMNA P02545 1/20 0.39
GRM7 Q14831 2/20 0.39
ANPEP P15144 1/20 0.38
KDM4E B2RXH2 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1640413 0.86 POLB (0.41) SMN1; SMN2TSHRFABP7FABP5GRM7
SCHEMBL29929760 0.86 POLB (0.41) SMN1; SMN2TSHRFABP7FABP5GRM7
SCHEMBL29559032 0.78 ALDH1A1 (0.53) SMN1; SMN2ALDH1A1MAPTGAATSHR
SCHEMBL2083786 0.78 ALDH1A1 (0.53) SMN1; SMN2ALDH1A1MAPTGAATSHR
SCHEMBL3948845 0.78 MAPT (0.56) SMN1; SMN2ALDH1A1MAPTGAATSHR
SCHEMBL30702212 0.78 MAPT (0.56) SMN1; SMN2ALDH1A1MAPTGAATSHR
SCHEMBL468628 0.76 KMT2A (0.40) TSHRGRM7ANPEPMEN1KMT2A
SCHEMBL8398009 0.75 MMP3 (0.54) SMN1; SMN2MAPTGAATSHRNPSR1
SCHEMBL29443025 0.75 AKR1C3 (0.50) SMN1; SMN2MAPTGAAFABP7FABP5
SCHEMBL289302 0.75 AKR1C3 (0.50) SMN1; SMN2MAPTGAAFABP7FABP5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8921359-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, INC. (US) 2014-12-30 US disclosed
EP-2324032-B1 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS INC (US) 2014-10-01 EP disclosed
US-20130317014-A1 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS, INC. 2013-11-28 US disclosed
US-8450308-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, INC. (US) 2013-05-28 US disclosed
EP-2084125-B1 AMINOBENZOCYCLOHEPTENE DERIVATIVES, METHODS FOR PREPARING THE SAME AND USES THEREOF IN THERAPY UNIV HAUTE ALSACE (FR) 2012-01-11 EP disclosed
US-20110218192-A1 Inhibitors Of Beta-Secretase VITAE PHARMACEUTICALS, INC. (US) 2011-09-08 US disclosed
EP-2084125-A1 AMINOBENZOCYCLOHEPTENE DERIVATIVES, METHODS FOR PREPARING THE SAME AND USES THEREOF IN THERAPY Universite De Haute Alsace (FR) 2009-08-05 EP disclosed
WO-2008059141-A1 AMINOBENZOCYCLOHEPTENE DERIVATIVES, METHODS FOR PREPARING THE SAME AND USES THEREOF IN THERAPY UNIVERSITE DE HAUTE ALSACE (FR) 2008-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110218192-A1 Inhibitors Of Beta-Secretase BACE1, BACE2, APP SMN1; SMN2 769/4885ALDH1A1 2484/4885MAPT 61/4885
US-20130317014-A1 INHIBITORS OF BETA-SECRETASE BACE1, BACE2, APP SMN1; SMN2 769/4885ALDH1A1 2484/4885MAPT 61/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.